Drug Trial Radar · NCT03811080
Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Non Erosive Reflux Disease
Last checked: Nov 19, 2026Latest source record: Jun 25, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
327
Planned (sponsor's estimate)
Start
Feb 7, 2019
Primary completion
Feb 2020
Study completion Feb 2020
Sponsor
- Lead sponsor
- Daewoong Pharmaceutical Co. LTD.Industry
- Sponsor type
- Industry
- First posted
- Jan 22, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to demonstrate the superiority of efficacy of DWP14012, once daily (QD), compared to placebo in patients with non-erosive reflux disease at Week 4.
Conditions
- Non-Erosive Gastroesophageal Reflux Disease
Interventions
DWP14012 A mgDrug
The participants will receive treatment of DWP14012 A mg, tablet, orally, once daily and DWP14012 B mg placebo-matching tablet, orally, once daily for up to 4 weeks.
DWP14012 B mgDrug
The participants will receive treatment of DWP14012 B mg, tablet, orally, once daily and DWP14012 A mg placebo-matching tablet, orally, once daily for up to 4 weeks.
PlaceboDrug
The participants will receive treatment of DWP14012 A mg placebo-matching tablet, orally, once daily and DWP14012 B mg placebo-matching tablet, orally, once daily for up to 4 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- 1. Percentage of patients with complete resolution of major symptoms (heartburn and acid regurgitation) at 4-weekTime frame: 4 week
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hanyang University Medical Center
Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.